Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Jun 16, 2015
Insider Transaction Report
Form 4
Rosiello Robert L.
EVP, Chief Financial Officer
Transactions
- Purchase
Common Stock, no par value
2015-06-12$232.51/sh+12,900$2,999,379→ 12,900 total
Footnotes (1)
- [F1]This number represents the weighted average purchase price for all sales of common stock purchased by the reporting officer.